Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - metoclopramide hydrochloride - tablet - 10 milligram(s) - propulsives; metoclopramide

New Zealand - English - Medsafe (Medicines Safety Authority)

biomed limited - methadone hydrochloride 5 mg/ml;   - oral solution - 5 mg/ml - active: methadone hydrochloride 5 mg/ml   excipient: purified water - oral methadone is used in detoxification and maintenance treatment as a substitute for heroin or other morphine-like drugs to suppress the opiate-agonist abstinence syndrome in patients who are dependent on these drugs.

Ireland - English - HPRA (Health Products Regulatory Authority)

le vet beheer b.v. - metoclopramide (as hydrochloride monohydrate) (equivalent to metoclopramide hydrochloride ph. eur.) - solution for injection - 5 mg/ml - metoclopramide - canine, feline - neurological preparations

Uganda - English - National Drug Authority

abacus pharma (a) ltd. - metoclopramide hydrochloride - parenteral ordinary ampoules - 5 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - metoclopramide hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - indications as at 23 july 2001: adults (20 years or older) * relief of nausea and vomiting associated with migraine, cancer therapy (chemotherapy or radiation), malignant disease, labour, infectious disease and uraemia * control of post operative vomiting * assist in small bowel intubation. metoclopramide is of little benefit for the prevention or treatment of motion sickness. young adults and children metoclopramide should be restricted to the following conditions when used to treat children and young adults under 20 years of age because of the risk of adverse effects. * severe intractable vomiting of known cause * vomiting associated with radiation therapy or intolerance to cytotoxic drugs * assist in small bowel intubation. young adults and children (over 1 year of age)*metoclopramide should be restricted to the following conditions and only used as second line therapy, when used to treat children and young adults under 20 years of age because of the risk of adverse effects: *severe intractable vomiting o

Singapore - English - HSA (Health Sciences Authority)

dch auriga singapore - metoclopramide hcl eqv anhydrous metoclopramide hcl - injection - 5 mg/ml - metoclopramide hcl eqv anhydrous metoclopramide hcl 5 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 5 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; titanium dioxide; microcrystalline cellulose; macrogol 6000; purified talc; hypromellose; stearic acid; colloidal anhydrous silica - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 5 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; titanium dioxide; microcrystalline cellulose; macrogol 6000; purified talc; hypromellose; stearic acid; colloidal anhydrous silica - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation